Buy Or Sell Opportunity • Jul 21
Now 24% overvalued Over the last 90 days, the stock has fallen 25% to CN¥14.09. The fair value is estimated to be CN¥11.39, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 47% in 2 years. Earnings are forecast to grow by 42% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥16.12, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 19x in the Chemicals industry in China. Negligible returns to shareholders over past three years. Ankündigung • Jun 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2026 Results on Aug 22, 2026 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2026 results on Aug 22, 2026 Declared Dividend • Apr 27
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 30th April 2026 Payment date: 30th April 2026 Dividend yield will be 1.6%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is well covered by both earnings (47% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 50% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • Mar 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q1, 2026 Results on Apr 21, 2026 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q1, 2026 results on Apr 21, 2026 Reported Earnings • Mar 30
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.71 (up from CN¥0.61 in FY 2024). Revenue: CN¥3.75b (up 19% from FY 2024). Net income: CN¥278.5m (up 17% from FY 2024). Profit margin: 7.4% (down from 7.5% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.7%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Ankündigung • Mar 28
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 20, 2026 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 20, 2026, at 14:00 China Standard Time. Location: No. 16, Xinyuan Avenue, Hi-tech Zone, Chengdu, Sichuan China Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥18.40, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 23x in the Chemicals industry in China. Total returns to shareholders of 17% over the past three years. Reported Earnings • Feb 10
Full year 2025 earnings released: EPS: CN¥0.71 (vs CN¥0.61 in FY 2024) Full year 2025 results: EPS: CN¥0.71 (up from CN¥0.61 in FY 2024). Revenue: CN¥3.75b (up 19% from FY 2024). Net income: CN¥281.1m (up 18% from FY 2024). Profit margin: 7.5% (in line with FY 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Ankündigung • Dec 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 28, 2026 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 28, 2026 Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥21.09, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 24x in the Chemicals industry in China. Total returns to shareholders of 28% over the past three years. Reported Earnings • Oct 22
Third quarter 2025 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.19 (up from CN¥0.14 in 3Q 2024). Revenue: CN¥943.8m (down 3.1% from 3Q 2024). Net income: CN¥74.9m (up 32% from 3Q 2024). Profit margin: 7.9% (up from 5.8% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: CN¥0.21 (vs CN¥0.16 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.21 (up from CN¥0.16 in 2Q 2024). Revenue: CN¥928.7m (up 36% from 2Q 2024). Net income: CN¥83.2m (up 35% from 2Q 2024). Profit margin: 9.0% (in line with 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥24.32, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 18% over the past three years. New Risk • Jul 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.9% average weekly change). Profit margins are more than 30% lower than last year (7.7% net profit margin). Ankündigung • Jul 02
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥20.10, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 21x in the Chemicals industry in China. Total loss to shareholders of 5.1% over the past three years. Ankündigung • May 09
Chengdu Guibao Science & Technology Co.,Ltd. Announces Director Appointments Chengdu Guibao Science & Technology Co.,Ltd. at its EGM held on May 7, 2025, approved: Election and nomination of non-independent and independent directors: Zhao Kexing, non-independent director; Liu Qi, non-independent director; Wang Jiayu, non-independent director; Yi Yang, independent director. Declared Dividend • May 05
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 12th May 2025 Payment date: 12th May 2025 Dividend yield will be 1.6%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by both earnings (44% earnings payout ratio) and cash flows (56% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 78% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Ankündigung • Apr 24
Chengdu Guibao Science & Technology Co.,Ltd. Approves Cash Dividend for 2024 Chengdu Guibao Science & Technology Co.,Ltd. at its Annual General Meeting held on 21 April 2025 approved cash dividend of CNY 3.00000000 per 10 shares (tax included) for 2024. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥17.82, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.42 per share. Ankündigung • Apr 01
Chengdu Guibao Science & Technology Co.,Ltd. Announces Profit Distribution Proposal for the Year 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced profit distribution proposal final Cash dividend/10 shares (tax included) is CNY 3.000000 for the year 2024. Ankündigung • Mar 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q1, 2025 Results on Apr 15, 2025 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q1, 2025 results on Apr 15, 2025 Reported Earnings • Mar 30
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.61 (down from CN¥0.81 in FY 2023). Revenue: CN¥3.16b (up 21% from FY 2023). Net income: CN¥237.5m (down 25% from FY 2023). Profit margin: 7.5% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 6.7%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year and the company’s share price has also fallen by 1% per year. Ankündigung • Mar 29
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 21, 2025 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 21, 2025, at 14:00 China Standard Time. Location: 6F, No. 16, Xinyuan Avenue, Hi-tech Zone, Chengdu, Sichuan China New Risk • Mar 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (dividend per share is over 7x cash flows per share). Share price has been volatile over the past 3 months (8.0% average weekly change). Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥18.32, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Chemicals industry in China. Total loss to shareholders of 9.5% over the past three years. New Risk • Feb 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (dividend per share is over 7x cash flows per share). Share price has been volatile over the past 3 months (8.8% average weekly change). Ankündigung • Dec 31
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (dividend per share is over 7x cash flows per share). Share price has been volatile over the past 3 months (11% average weekly change). Valuation Update With 7 Day Price Move • Nov 19
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥19.67, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 18x in the Chemicals industry in China. Total loss to shareholders of 14% over the past three years. Major Estimate Revision • Oct 30
Consensus EPS estimates fall by 27%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from CN¥3.18b to CN¥3.23b. EPS estimate fell from CN¥0.896 to CN¥0.65 per share. Net income forecast to grow 48% next year vs 51% growth forecast for Chemicals industry in China. Consensus price target of CN¥18.20 unchanged from last update. Share price fell 2.3% to CN¥14.31 over the past week. Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.23 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.23 in 3Q 2023). Revenue: CN¥974.1m (up 36% from 3Q 2023). Net income: CN¥56.7m (down 38% from 3Q 2023). Profit margin: 5.8% (down from 13% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Ankündigung • Sep 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q3, 2024 Results on Oct 22, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to CN¥14.18, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.73 per share. Major Estimate Revision • Sep 04
Consensus EPS estimates increase by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥2.96b to CN¥3.21b. EPS estimate increased from CN¥0.83 to CN¥0.915 per share. Net income forecast to grow 43% next year vs 45% growth forecast for Chemicals industry in China. Consensus price target of CN¥18.20 unchanged from last update. Share price rose 3.4% to CN¥11.00 over the past week. Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.20 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.16 (down from CN¥0.20 in 2Q 2023). Revenue: CN¥684.0m (up 3.2% from 2Q 2023). Net income: CN¥61.6m (down 20% from 2Q 2023). Profit margin: 9.0% (down from 12% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Ankündigung • Jun 29
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Major Estimate Revision • Jun 15
Consensus revenue estimates fall by 15% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.35b to CN¥2.83b. EPS estimate fell from CN¥0.978 to CN¥0.72 per share. Net income forecast to grow 8.7% next year vs 50% growth forecast for Chemicals industry in China. Consensus price target of CN¥18.20 unchanged from last update. Share price was steady at CN¥13.67 over the past week. Declared Dividend • Apr 29
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 30th April 2024 Payment date: 30th April 2024 Dividend yield will be 2.2%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by both earnings (39% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 106% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Apr 22
Now 31% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.7% to CN¥13.06. The fair value is estimated to be CN¥18.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has grown by 6.5%. Revenue is forecast to grow by 81% in 2 years. Earnings are forecast to grow by 76% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥14.08, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 8.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.21 per share. Price Target Changed • Apr 11
Price target decreased by 13% to CN¥18.20 Down from CN¥20.94, the current price target is an average from 2 analysts. New target price is 14% above last closing price of CN¥16.01. Stock is down 6.9% over the past year. The company is forecast to post earnings per share of CN¥0.98 for next year compared to CN¥0.81 last year. Ankündigung • Mar 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q1, 2024 results on Apr 20, 2024 Reported Earnings • Mar 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.64 in FY 2022). Revenue: CN¥2.61b (down 3.3% from FY 2022). Net income: CN¥315.2m (up 26% from FY 2022). Profit margin: 12% (up from 9.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 3.4%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Ankündigung • Mar 29
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 19, 2024 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 19, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chengdu, Sichuan China Ankündigung • Feb 22
Chengdu Guibao Science & Technology to Buy Hot Melt Adhesive Firm Chengdu Guibao Science & Technology Co.,Ltd. (SZSE:300019) said it plans to buy hot melt adhesive firm with estimated valuation of CNY 480 million ($66.72 million). Reported Earnings • Feb 03
Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.64 in FY 2022) Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.64 in FY 2022). Revenue: CN¥2.61b (down 3.3% from FY 2022). Net income: CN¥315.2m (up 26% from FY 2022). Profit margin: 12% (up from 9.3% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥12.47, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in China. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.41 per share. Ankündigung • Dec 29
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 29, 2024 Reported Earnings • Oct 20
Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.16 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.23 (up from CN¥0.16 in 3Q 2022). Revenue: CN¥718.8m (up 13% from 3Q 2022). Net income: CN¥91.2m (up 45% from 3Q 2022). Profit margin: 13% (up from 9.9% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Ankündigung • Sep 30
Chengdu Guibao Science & Technology Co.,Ltd. to Report Q3, 2023 Results on Oct 19, 2023 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report Q3, 2023 results on Oct 19, 2023 Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.15 in 2Q 2022). Revenue: CN¥662.9m (down 6.9% from 2Q 2022). Net income: CN¥77.3m (up 28% from 2Q 2022). Profit margin: 12% (up from 8.4% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 4% per year. Ankündigung • Jul 01
Chengdu Guibao Science & Technology Co.,Ltd. to Report First Half, 2023 Results on Aug 12, 2023 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report first half, 2023 results on Aug 12, 2023 Reported Earnings • Mar 26
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.64 (down from CN¥0.70 in FY 2021). Revenue: CN¥2.69b (up 5.4% from FY 2021). Net income: CN¥250.3m (down 6.5% from FY 2021). Profit margin: 9.3% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 20% per year. Reported Earnings • Feb 12
Full year 2022 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in FY 2021) Full year 2022 results: EPS: CN¥0.64 (down from CN¥0.70 in FY 2021). Revenue: CN¥2.69b (up 5.4% from FY 2021). Net income: CN¥250.2m (down 6.5% from FY 2021). Profit margin: 9.3% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 19% per year. Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Xianye Tang is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 25
Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.17 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.16 (down from CN¥0.17 in 3Q 2021). Revenue: CN¥637.6m (down 5.4% from 3Q 2021). Net income: CN¥63.0m (down 7.7% from 3Q 2021). Profit margin: 9.9% (in line with 3Q 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 18% per year. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥18.17, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 160% over the past three years. Price Target Changed • Aug 23
Price target increased to CN¥25.83 Up from CN¥19.94, the current price target is an average from 3 analysts. New target price is 33% above last closing price of CN¥19.41. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.92 for next year compared to CN¥0.70 last year. Reported Earnings • Aug 21
Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.17 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.15 (down from CN¥0.17 in 2Q 2021). Revenue: CN¥711.9m (up 9.6% from 2Q 2021). Net income: CN¥60.1m (down 7.6% from 2Q 2021). Profit margin: 8.4% (down from 10.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 32%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥20.92, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 216% over the past three years. Ankündigung • May 02
Chengdu Guibao Science & Technology Co.,Ltd. Announces Board Appointments Chengdu Guibao Science & Technology Co.,Ltd. approved the election of Wu Mengying, Liu Zhumeng, Guo Bin and Yang Limei as non-independent directors,the company also announced the election of Wang jin, Wang Yimin and Tang Xianye as independent Directors, at the EGM held on April 28, 2022. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. 3 independent directors (9 non-independent directors). Director Rundong Yue was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Ankündigung • Apr 23
Chengdu Guibao Science & Technology Co.,Ltd. Proposes Cash Dividend on A Shares for the Year 2021, Payable on April 28, 2022 Chengdu Guibao Science & Technology Co.,Ltd. proposed cash dividend per ten shares (tax included) on A shares of CNY 3.00000000 for the year 2021, payable on April 28, 2022. Record date to be April 27, 2022. Ex-date to be April 28, 2022. Ankündigung • Apr 20
Chengdu Guibao Science & Technology Co.,Ltd. Approves 2021 Profit Distribution Plan Chengdu Guibao Science & Technology Co.,Ltd. approved cash dividend/10 shares (tax included): CNY 3.00000000 for the year 2021 at its Annual General Meeting held on 15 April 2022. Reported Earnings • Apr 17
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.081 in 1Q 2021). Revenue: CN¥669.6m (up 87% from 1Q 2021). Net income: CN¥42.7m (up 51% from 1Q 2021). Profit margin: 6.4% (down from 7.9% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.6%. Earnings per share (EPS) missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 23%, compared to a 50% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 26% per year. Ankündigung • Mar 31
Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 15, 2022 Chengdu Guibao Science & Technology Co.,Ltd., Annual General Meeting, Apr 15, 2022, at 14:00 China Standard Time. Agenda: To approve 2021 work report of the board of directors; to consider the 2021 work report of the supervisory committee; to consider the 2021 annual report and its summary; 2021 annual accounts; to consider the 2021 audited financial report; to consider the 2021 profit distribution plan; to consider the application for comprehensive credit line to banks by the Company and its wholly-owned subsidiaries; to consider the provision of guarantee for the bank comprehensive credit line applied for by wholly-owned subsidiaries; Cash management with idle funds; 2022 appointment of financial audit firm; to consider the repurchase and cancellation of some restricted stocks; and to consider the amendments to the Company's articles of association and authorization to the board to handle the industrial and commercial registration amendment. Ankündigung • Mar 29
Chengdu Guibao Science & Technology Co.,Ltd. Proposes Final Cash Dividend for the Year 2021 Chengdu Guibao Science & Technology Co.,Ltd. proposed final cash dividend/10 shares (tax included): CNY 3.00000000 for the year 2021. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥17.10, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 135% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.09 per share. Buying Opportunity • Mar 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be CN¥26.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% per annum over the last 3 years. Earnings per share has grown by 42% per annum over the last 3 years. Buying Opportunity • Feb 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CN¥25.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% per annum over the last 3 years. Earnings per share has grown by 42% per annum over the last 3 years. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.19 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥673.9m (up 69% from 3Q 2020). Net income: CN¥68.3m (up 8.8% from 3Q 2020). Profit margin: 10% (down from 16% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥17.76, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 188% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.79 per share. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥23.53, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 311% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.63 per share. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 26% share price gain to CN¥25.08, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 314% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.65 per share. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.19 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥649.5m (up 67% from 2Q 2020). Net income: CN¥65.1m (up 6.0% from 2Q 2020). Profit margin: 10.0% (down from 16% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 51% per year. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥21.85, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 239% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.80 per share. Reported Earnings • Apr 21
First quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.031 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥358.7m (up 130% from 1Q 2020). Net income: CN¥28.3m (up 172% from 1Q 2020). Profit margin: 7.9% (up from 6.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 28
Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.40 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CN¥1.52b (up 50% from FY 2019). Net income: CN¥201.0m (up 53% from FY 2019). Profit margin: 13% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 24
Chengdu Guibao Science & Technology Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021 Chengdu Guibao Science & Technology Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 27, 2021 Is New 90 Day High Low • Feb 05
New 90-day low: CN¥15.19 The company is down 2.0% from its price of CN¥15.53 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥18.52, the stock is trading at a trailing P/E ratio of 33.5x, up from the previous P/E ratio of 28.7x. This compares to an average P/E of 36x in the Chemicals industry in China. Total returns to shareholders over the past three years are 85%. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥18.44, the stock is trading at a trailing P/E ratio of 33.3x, down from the previous P/E ratio of 39.7x. This compares to an average P/E of 37x in the Chemicals industry in China. Total returns to shareholders over the past three years are 101%. Valuation Update With 7 Day Price Move • Nov 20
Market bids up stock over the past week After last week's 17% share price gain to CN¥23.65, the stock is trading at a trailing P/E ratio of 42.8x, up from the previous P/E ratio of 36.7x. This compares to an average P/E of 39x in the Chemicals industry in China. Total returns to shareholders over the past three years are 178%. Valuation Update With 7 Day Price Move • Nov 12
Market bids up stock over the past week After last week's 30% share price gain to CN¥19.98, the stock is trading at a trailing P/E ratio of 36.1x, up from the previous P/E ratio of 27.7x. This compares to an average P/E of 39x in the Chemicals industry in China. Total returns to shareholders over the past three years are 107%. Is New 90 Day High Low • Nov 12
New 90-day high: CN¥19.98 The company is up 37% from its price of CN¥14.61 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥183.0m, up 44% from the prior year. Total revenue was CN¥1.29b over the last 12 months, up 34% from the prior year.